News & Updates
Filter by Specialty:
Infection + vaccination = The best protection against COVID-19?
Individuals with a prior COVID-19 infection and who are fully vaccinated against COVID-19 appear to have the greatest immunity to the virus, according to the SIREN* study.
Infection + vaccination = The best protection against COVID-19?
13 Jun 2022Azithromycin improves asthma control, cuts exacerbations in children
In the treatment of children with poorly controlled asthma, the use of azithromycin helps improve asthma control and reduce exacerbations, according to a study.
Azithromycin improves asthma control, cuts exacerbations in children
11 Jun 2022OKINADA: TNF inhibition disappoints in knee osteoarthritis
Short-term tumour necrosis factor (TNF) inhibition with adalimumab falls short of producing improvements in patients with radiographic knee osteoarthritis, according to the proof-of-concept OKINADA trial presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.
OKINADA: TNF inhibition disappoints in knee osteoarthritis
10 Jun 2022Obefazimod 50 mg for rheumatoid arthritis delivers in phase II trial
The investigational drug ABX464, also known as obefazimod, helps reduce disease activity in patients with rheumatoid arthritis (RA), according to the results of a phase II trial. The 50-mg dose is well tolerated, while the higher dose is associated with mild-to-moderate adverse effects resulting in treatment discontinuation.
Obefazimod 50 mg for rheumatoid arthritis delivers in phase II trial
10 Jun 2022Novel PDE4 inhibitor slows IPF progression
Treatment with BI 1015550, a novel investigational phosphodiesterase 4 (PDE4) inhibitor, slows lung function decline in patients with idiopathic pulmonary fibrosis (IPF) with or without background antifibrotic therapy, according to a 12-week phase II trial data presented at ATS 2022.
Novel PDE4 inhibitor slows IPF progression
10 Jun 2022Women with rheumatic diseases face adverse pregnancy outcomes
Pregnancies in women with rheumatic and systemic autoimmune diseases—including systemic lupus erythematosus, spondyloarthritis, and rheumatoid arthritis—pose significant health risks and are likely to lead to unfavourable outcomes, according to several studies presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.